header-test
Utility Nav

For U.S. Healthcare Professionals only.

For U.S. Healthcare Professionals only.

Next Page Icon

Indication

Additional safety data for COBENFY in adults with schizophrenia

The majority of patients did not experience clinically significant weight gain from Week 5 to Week 521

Weight Change Over the 52-Week Treatment Period1
EMERGENT-4 & -5

On average, patients lost 5.6 lbs in a year-long extension trial1

  • 17.6% of patients had a decrease in body weight of ≥7%
  • 4.1% of patients had an increase in body weight of ≥7%
96% of patients did not experience clinically significant weight gain

of patients did not experience clinically significant weight gain (≥7%).1

View short and long-term study designs

Safety and tolerability were assessed in three 5-week randomized, double-blind, placebo-controlled studies. EMERGENT-2 (N=252) and EMERGENT-3 (N=256) were phase 3 trials and EMERGENT-1 (N=182 was a phase 2 trial. Long-term safety and tolerability were assessed in two 52-week, phase 3, open-label studies; EMERGENT-4 (n=152), an extension of EMERGENT-2 and EMERGENT-3, and EMERGENT-5 (n=566).1 See additional study design details.

Select metabolic changes were low in short-term studies1

Shifts From Baseline to End Point in EMERGENT -1, -2, & -3 (pooled data)1

Metabolic side effects in EMERGENT trial

Movement disorders: short- and long-term safety data

Movement disorders with COBENFY

Movement Disorders With COBENFY1
52-week trials (EMERGENT-4 & -5)

Movement scales assessing movement disorders were stable over 52 weeks3

AIMS=Abnormal Involuntary Movement Scale; BARS=Barnes Akathisia Rating Scale; EPS=extrapyramidal symptoms; SAS=Simpson Angus Scale; Wk=week.

See how COBENFY works

Explore the efficacy of COBENFY

Learn how to get patients started on
COBENFY

References: 

  1. Data on file. Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Boston, MA.
  2. COBENFY. Prescribing Information. Bristol Myers Squibb Company; 2024.
  3. Novak K, Watson C, Claxton A, Marcus R, Brannan SK. Low long-term risk of EPS with muscarinic agonist KarXT (xanomeline and trospium chloride). Poster presented at: American Society of Clinical Psychopharmacology Annual Meeting; May 28-31, 2024; Miami Beach, FL.


Cobenfy, Cobenfy Cares, and the Cobenfy logo are trademarks of Karuna Therapeutics, Inc., a Bristol Myers Squibb company.
© 2024 Bristol-Myers Squibb Company. 1629-US-2400140 10/24